Pharmaceutical Technology Europe-09-01-2010

Pharmaceutical Technology Europe

No one can deny the power of social media; it has revolutionised communication and empowered consumers, creating a medium that allows the free flow of information with no authority to control it.

Manufacturing
Pharmaceutical Technology Europe

September 01, 2010

A Strengths, Weaknesses, Opportunities and Threats analysis of the biosimilars market is given.

Industry Insider
Pharmaceutical Technology Europe

September 01, 2010

Despite the poor economic climate, large-scale mergers and acquisitions in the pharmaceutical industry struck back with a vengeance in 2009.

Pharmaceutical Technology Europe

In an increasingly competitive landscape, outsourcing providers are under mounting pressure to get their name out there and secure new and repeat business.

Pharmaceutical Technology Europe
Special Feature

September 01, 2010

The economic crisis has affected outsourcing providers in several ways.

Special Feature
Pharmaceutical Technology Europe

September 01, 2010

India has evolved from a low-cost region to an area with extensive technical capability and high quality standards.

Pharmaceutical Technology Europe

In light of the impressive size and predicted growth of the market, there has been a rising interest in the development of biosimilars.

Interview
Pharmaceutical Technology Europe

September 01, 2010

The manufacture of high potency active pharmaceutical ingredients (HPAPIs) is on the rise with R&D projects showing a continuing interest in these products.

Pharmaceutical Technology Europe
News

September 01, 2010

Pharma struggling with social media; Opportunities in the OTC market

Pharmaceutical Technology Europe

Industry experts discuss the merits of continuous processing technology and explain why pharma manufacturers should realize the benefits these technologies offer.

Analytics
Pharmaceutical Technology Europe

September 01, 2010

Utilizing integrated active radio frequency identification (RFID) and real-time asset management systems can yield commercial and compliance benefits.

Special Feature
Pharmaceutical Technology Europe

September 01, 2010

When assessing the competencies of an outsourcing service provider, sponsor companies must pay a great deal of attention to the cGMP compliance level of the provider.

Pharmaceutical Technology Europe
Manufacturing

September 01, 2010

Many hurdles lie between a biosimilar and success on the market. In particular, there are three main questions that companies will be asking themselves.

Pharmaceutical Technology Europe

A case study describing how Lean can drive the creation of an improved culture within pharmaceutical companies.

Manufacturing
Pharmaceutical Technology Europe

September 01, 2010

Both biosimilar and generic drugs have an abbreviated approval process; however, the clinical trial requirements differ enormously.

Special Feature
Pharmaceutical Technology Europe

September 01, 2010

How to find the right partner in Asia–Pacific is a very complex question and there is no uniform answer.

Pharmaceutical Technology Europe

One particularly crucial parameter for nasal sprays is the size of the droplets produced during actuation, which can potentially impact bioavailability.

Pharmaceutical Technology Europe
Manufacturing

September 01, 2010

Last year, the global market for biological products exceeded $125 billion, accounting for 17% of the total market for pharma/biopharma products.